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GTPaseRac. Another mode is amoeboid motility, which involves
formation of blebs – hollowmembrane protrusions extruded from
the cell surface by actin-myosin contraction. Amoeboid motility
does not need both pronounced cell-substrate adhesions and
MMPs activity and required increase of activity of small GTPase
Rho. Fibroblasts and scattered epithelial cells migrate by mes-
enchymal mode, while blood cells – lymphocytes or macrophages
mainly use amoeboid mode for migration. It was shown that
some treatments cause transition from one motility mode to
another. Switches from mesenchymal to amoeboid motility and
opposite are called mesenchymal-amoeboid transition (MAT)
and amoeboid -mesenchymal transition (AMT) respectively. The
ability of cells for such transitions was named as plasticity of
migration. We compared the plasticity of migration of normal
and tumor cells. To study plasticity of mesenchymally migrated
cells (MAT) we choose fibrosarcoma cells HT1080 as tumor and
non-transformed subcutaneous fibroblasts 1036 as normal
counterpart. To study AMT we choose a few lines of myeloid
leukemia THP1, K562, KG1 in contrast to normal leukocytes
obtained from healthy donors. We showed that fibrosarcoma cells
in opposite to non-transformed fibroblasts could undergo MAT
under treatments, which limited mesenchymal migration. Two
approaches to limit mesenchymal motility of cells were used.
One was decrease of substrate adhesiveness by treatment of
coverslips with PolyHema solutions, which simulated the
alteration of environmental conditions during cell migration.
The other approach was influence on cellular pathways regulated
cell motility. We used CK666, the inhibitor of Arp2/3 activity,
which stopped actin polymerization and thus lamellipodia
formation through Arp2/3 dependent mechanism. We showed
that under both treatments the fraction of tumor cells switched
from lamellipodia formation to blebbing and thus underwent
MAT, while in non-transformed fibroblasts these treatments led
to retraction of lamellipodia and significant failure of motility.
Both leukemia cells and leucocytes of healthy donors showed
blebs formation (amoeboid motility). We induced transition to
mesenchymal motility by alteration of culture conditions. The
first approach was the increase of substrate adhesiveness by
treatment with fibronectin. Another way was to inhibit of small
GTPase Rho activity. In result of both treatments, leukemia cells
switched from amoeboid to mesenchymal motility (underwent
AMT), but leucocytes of healthy donor could not do such
transition. For the first time it was shown that AMT is features
of leukemia cells but not leucocytes from healthy donors. Both
MAT and AMT are reversible, meaning that cells exhibiting
plasticity could change motility mode in dependence on
environment. Our results demonstrate that tumor cells of differ-
ent origin could transit from one mode of motility to another
and normal cells could not undergo such transitions. We also
investigate the effectiveness of amoeboid and mesenchymal
motility during migration in different environments. It was
shown that the mesenchymal motility is more effective for 2D
migration, while the amoeboid motility is more effective in 3D
conditions. During dissemination, cells go beyond the borders of
original tissues and pass through environment with different
properties. The plasticity of migration triggered by alteration of
entire or internal conditions dramatically increases ability of cells
to disseminate. The ability of tumor cells to plasticity permits
them to choose optimal mode for migration, thus leading to
metastasis development.
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Background: Tamoxifen, a selective estrogen receptor modula-
tor, remains a standard of endocrine therapy for estrogen recep-
tor alpha (ERa) positive breast cancer (Goldhirsch et al., 2013).
Despite well-known advantages of tamoxifen treatment, approx-
imately one third of patients experience a relapse or disease
progression due to tamoxifen resistance (Osborne et al., 2011).
Identification of additional molecular markers associated with
both ER genomic and non-genomic pathways could be very useful
to help identify patients who will likely benefit from such endo-
crine treatment. The aim of the present study was to evaluate
the influence of the distribution pattern of ERa expression as well
as ESR1, TGF-bR1 and IGF-1R single nucleotide polymorphisms
(SNPs) and the expression of growth factors receptors on disease
progression in breast cancer patients of Russian Western Siberian
population treated by adjuvant tamoxifen.
Materials and methods: Formalin-fixed paraffin-embedded
tumor tissue samples were retrospectively collected from 97
hormone receptor-positive breast cancer patients treated with
adjuvant tamoxifen at the Tomsk Cancer Research Institute.
Genotypes for ESR1 +30T>C (rs2077647), ESR12014G>A
(rs2228480), IVS7+24G>A (rs334354) and IGF-1R (rs2016347) SNPs
were detected by a TaqMan assay. The distribution patterns of
ERa expression and EGFR, TGF-bR1, IGF-1R protein expression
were determined using the immunohistochemistry. Patients
who developed distant metastasis or recurrence after tamoxifen
treatment during the follow-up period were defined as tamoxifen
resistance (TR) group, while distant metastasis-free patients were
analyzed as tamoxifen sensitive (TS) group.
Results: We found that the heterogeneous distribution of ERa
expression was statistically significant related with poor progno-
sis of tamoxifen treated patients (p = 0.021). Similarly, we showed
high EGFR expression in TR group compared to TS patients (80.0%
vs. 41.9% respectively, p = 0.009). Additionally, EGFR expression
and distribution pattern of ERa expression were significantly
associated with response to tamoxifen and this association
remained significant in both univariate and multivariate analysis.
Our results demonstrate that the ESR12014A mutant allele
carriers were more prevalent in TR patients than in TS group
(26.3% vs. 8.0%, respectively, p = 0.009). Concerning the IGF-1R
polymorphism, we found that TT homozygous carriers were more
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frequent in the TS group compared with TR group (p = 0.043). A
significant association between IVS7+24G>A SNP and high TGF-
bR1 protein expression was observed (p = 0.044). Nonetheless,
among all studied polymorphisms only ESR12014G>A SNP was
correlated with a heterogeneous distribution of ERa expression
(r = 0.353, p = 0.016).
Conclusion: These data suggest that the distribution pattern of
ERa expression, EGFR expression and ESR1 2014G>A genetic
variation could be useful additional prognostic markers for
hormone receptor-positive breast cancer patients treated with
adjuvant tamoxifen.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.004
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Tumor markers play an important role in the identification of
human malignancies. It has been shown that the carcinoembry-
onic antigen (CEA, CEACAM5) is a promoter of metastasis in
epithelial cancers that is widely used as a clinical marker. The
aim of this study is to elucidate the network of genes that are
involved in the CEA-induced liver metastasis. Previously, we have
shown that CEA is accumulated in the lungs and livers of rats by
interacting with their macrophages. We identified and cloned a
new gene (CEAR) for the CEA-binding protein, which is located
on the surface of fixed liver macrophages, Kupffer cells (Bajenova
et al, 2001). It has been shown that the interaction of CEA and
CEAR proteins increases the production of IL-1, IL-10, IL-6,
TNF-a cytokines (Thomas et al, 2011). This interaction changes
the expression of liver adhesion molecules that enhances the
survival of cancer cells to the liver. We also suggested that CEA
synthesis by cancer cells may influence the E-cadherin adhesion
junction complexes and have shown that CEA production violates
the functional relationship between Ecadherin and its partners a-,
b- and p120 catenin. A new type of interaction was discovered
between the CEA and b-catenin and the increased amount of
b-catenin in the nuclei of CEA producing cells. The data show that
CEA production can cause the dissociation of cancer cells and
trigger cancer progression. The CEA synthesis also alters splicing
of p120 catenin protein and causes the release of soluble
E-cadherin. Previously, CEA and epithelial E-cadherin were
considered as independent tumor markers. Our data explain
the correlation between the elevated levels of CEA and the
increase in soluble E-cadherin in the progression of colorectal
cancer (Bajenova et al, 2014).
We carried out a comparative transcriptome analysis of CEA-
producing cell lines. The RNA transcriptome libraries were
obtained and sequenced. By pairwise comparisons of CEA pro-
ducing and non-producing cell lines using Cummerband pro-
gram, we selected the set of genes (90 total genes) whose
expression have been changed in the CEA-producing cell lines
(overexpressed or downregulated). The biological processes that
are linked to this differential gene expression were identified by
Gene Set Enrichment Analysis (GSEA). In total, 8 significantly
enriched GO terms related to the cellular components and biolog-
ical processes were identified. Using KEGG and GO databases, we
also identified the signaling pathways involved in the response to
CEA. These findings have direct medical application, since they
allow not only to establish the relationships between the existing
biomarkers but also to discover the new ones. These biomarkers
can be used for diagnosis and monitoring of metastatic carcino-
mas and for the drug development.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.005
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Discovery of new pharmacologically active small molecules is
an important and rapidly expanding area of modern molecular
pharmacology. Given a limited number of proteins that are drug-
gable, it is important to identify as many chemical effectors as
possible to define the best regimen of anti-cancer therapy in each
particular case. An E3 ubiquitin ligase, Mdm2, which mediates
ubiquitin-dependent degradation of the critical tumor suppressor
p53, is a promising target for small molecule inhibitors. Using a
hybrid approach which combines the rational design of small
molecules selected from the virtual library and the high-content
screening using cancer cell lines we discovered several new inhi-
bitors of the p53-Mdm2 interaction. These compounds were able
to activate and stabilize the p53 protein causing massive apopto-
sis preferably in p53-positive cells at rates higher than the well-
known inhibitor of Mdm2, Nutlin-3. The molecular mechanisms
of their action will be discussed.
As another example of rational design of potential anti-cancer
drugs, we will talk about artificial nano-Matrix-Imprinted -
Polymers (MIPs) that recognize the structure of peptides and
other biological molecules and thus dubbed as ‘‘plastic antibod-
ies”. We have generated such nanoparticles against the surface
region of the oncogenic receptor, EGFR, which is overexpressed
in many forms of solid tumors. Selection of the linear epitope
for creating ‘‘plastic antibodies” against the receptor was per-
formed by analysis of a three-dimensional structure of the pro-
tein. The obtained ‘‘plastic antibodies” were specific against the
epitope of EGFR. These plastic antibodies when loaded with a
genotoxic drug, doxorubicin, were able to specifically induce cell
death of breast cancer cell lines that overexpress the EGFR recep-
tor. Experiments in vivo using xenografts of breast cancer cell
lines pre-incubated with these plastic antibodies in nude mice
showed that they have a pronounced therapeutic effect. Further-
more, since the commercial drug, Cetuximab, recognizes an epi-
tope of EGFR, different from the one recognized by our plastic
antibodies, it is likely that the latter may increase the efficacy of
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